other Cancer Research Results

other, other: Click to Expand ⟱
Source:
Type:
custom
BPH, Benign Prostatic Hyperplasia: Click to Expand ⟱
Benign Prostatic Hyperplasia (BPH) is a noncancerous enlargement of the prostate gland that commonly occurs in older men.
- Increased DHT levels in prostatic tissue are associated with hyperplasia.
- An imbalance in IGF signaling might contribute to abnormal growth.
- Targeted therapies (such as 5α-reductase inhibitors and α-blockers).
-Avoid excessive amounts of saturated fat, such as those found in red meat, fried foods, and dairy products.
-a low-fat, cholesterol-free diet.
-foods rich in omega-3 fatty acids (salmon, nuts, flaxseed)
-stop taking over-the-counter cold remedies
-eat foods rich in β-sitosterol, green leafy vegetables, rice bran, wheat germ, peanuts, corn oils, nuts, and soybeans.
-Replace vegetable oils with olive or canola oil for cooking.
-Maintain appropriate weight and regular aerobic exercise.

Pharmaceuticals

Drug class Pharmaceutical Common brand name Primary mechanism Role in BPH Important adverse effects / cautions
α1-Adrenergic receptor antagonist
(α1-blocker)		 Tamsulosin Flomax Preferentially blocks α1A-adrenergic receptors in the prostate and bladder neck, reducing smooth-muscle tone. Rapid symptomatic improvement in urinary flow, hesitancy and incomplete emptying. Does not substantially shrink the prostate or prevent progression. Dizziness, orthostatic hypotension, nasal congestion and ejaculatory dysfunction. Associated with intraoperative floppy iris syndrome during cataract surgery.
Silodosin Rapaflo Highly selective α1A-adrenergic receptor antagonist that relaxes prostatic and bladder-neck smooth muscle. Rapid relief of moderate-to-severe lower urinary tract symptoms (LUTS). Ejaculatory dysfunction is relatively common; dizziness and orthostatic hypotension may occur. Dose adjustment may be required in renal impairment.
Alfuzosin Uroxatral Functionally uroselective α1-adrenergic receptor antagonist that reduces smooth-muscle contraction in the prostate and bladder neck. Rapid improvement of voiding symptoms, generally with less ejaculatory dysfunction than highly α1A-selective drugs. Dizziness, hypotension and possible QT-interval effects. Use cautiously with antihypertensive drugs and CYP3A4 inhibitors.
Doxazosin Cardura Non-uroselective α1-adrenergic receptor antagonist that relaxes prostate, bladder-neck and vascular smooth muscle. Improves BPH symptoms and can also lower blood pressure. Orthostatic hypotension, dizziness, fatigue and first-dose syncope. Dose titration is generally required.
Terazosin Hytrin Non-uroselective α1-adrenergic receptor antagonist affecting both urinary tract and vascular smooth muscle. Improves LUTS and may be useful when hypertension is also present. Orthostatic hypotension, dizziness, weakness and first-dose syncope. Requires gradual dose titration.
5α-Reductase inhibitor
(5-ARI)		 Finasteride Proscar Inhibits type II 5α-reductase, decreasing conversion of testosterone to dihydrotestosterone (DHT). Gradually reduces prostate volume and lowers the risk of acute urinary retention or BPH-related surgery, particularly in men with an enlarged prostate. Clinical benefit may require several months. Reduced libido, erectile or ejaculatory dysfunction and breast tenderness. Lowers serum PSA, which must be considered when interpreting PSA results.
Dutasteride Avodart Inhibits both type I and type II 5α-reductase, producing marked suppression of DHT. Reduces prostate volume and risk of BPH progression, urinary retention and surgery in men with prostatic enlargement. Reduced libido, erectile or ejaculatory dysfunction and breast effects. Lowers serum PSA. Pregnant persons should not handle leaking capsules.
Phosphodiesterase-5 inhibitor
(PDE5 inhibitor)		 Tadalafil Cialis Inhibits PDE5 and increases cyclic GMP signalling, promoting smooth-muscle relaxation in the lower urinary tract and pelvic vasculature. Improves LUTS with or without coexisting erectile dysfunction. The usual BPH regimen is once-daily therapy rather than as-needed dosing. Headache, flushing, dyspepsia, nasal congestion and back pain. Contraindicated with nitrate drugs; caution with hypotension and concurrent α-blockers.
Antimuscarinic
(anticholinergic)		 Solifenacin Vesicare Blocks muscarinic receptors in the bladder detrusor, reducing involuntary bladder contraction. Used alone or with an α1-blocker when urgency, frequency or urge incontinence persists despite treatment of the obstructive component. Dry mouth, constipation, blurred vision and possible urinary retention. Use cautiously when post-void residual urine is elevated.
Tolterodine Detrol Muscarinic receptor antagonist that reduces detrusor overactivity. Targets storage symptoms associated with BPH/LUTS. Dry mouth, constipation, cognitive effects and possible urinary retention.
Oxybutynin Ditropan Muscarinic receptor antagonist with direct antispasmodic activity on the bladder. May reduce urgency, frequency and urge incontinence. Dry mouth, constipation, blurred vision, heat intolerance and cognitive adverse effects, particularly in older adults.
Trospium Sanctura Peripherally acting muscarinic receptor antagonist with relatively limited penetration of the blood-brain barrier. Used for persistent bladder-storage symptoms. Dry mouth, constipation and urinary retention. Dose adjustment may be needed in renal impairment.
Darifenacin Enablex Preferentially antagonizes M3 muscarinic receptors in the bladder. Reduces urgency, frequency and urge incontinence. Constipation, dry mouth, blurred vision and possible urinary retention.
Fesoterodine Toviaz Muscarinic receptor antagonist that suppresses detrusor contractions. Used for persistent storage-predominant LUTS. Dry mouth, constipation and possible urinary retention; renal or hepatic dose adjustment may be necessary.
β3-Adrenergic receptor agonist Mirabegron Myrbetriq / Betmiga Activates β3-adrenergic receptors in the detrusor, relaxing the bladder during the storage phase. Used alone or with an α1-blocker for persistent urgency, frequency or urge incontinence associated with BPH/LUTS. May increase blood pressure; possible tachycardia and urinary retention. Avoid or use cautiously in severe uncontrolled hypertension.
Vibegron Gemtesa Selective β3-adrenergic receptor agonist that increases bladder storage capacity by relaxing the detrusor. Treats coexisting overactive-bladder or storage symptoms rather than reducing prostate enlargement. Headache, urinary tract infection and possible urinary retention, particularly in men with significant bladder-outlet obstruction.
Combination therapy Tamsulosin + dutasteride Jalyn / Duodart Combines rapid α1A-receptor blockade with long-term suppression of DHT. Used in symptomatic men with an enlarged prostate who require both rapid symptom relief and reduction of long-term progression risk. Combines α-blocker adverse effects with sexual and PSA-related effects of a 5-ARI.
Tadalafil + finasteride Entadfi Combines PDE5 inhibition with type II 5α-reductase inhibition. May provide earlier symptom improvement while finasteride gradually reduces prostate volume; may be useful when erectile dysfunction coexists. Contraindicated with nitrates. May cause headache, hypotension and sexual adverse effects. Product-specific duration restrictions may apply.
α1-Blocker + antimuscarinic or β3 agonist Various combinations Relaxes the prostate and bladder neck while separately suppressing detrusor overactivity or improving bladder storage. Considered when voiding symptoms improve with an α1-blocker but urgency, frequency or urge incontinence remains troublesome. Monitor post-void residual urine and symptoms of urinary retention. Adverse effects depend on the individual components.


Natural Products

Natural-product class Product / compound Common source Proposed mechanism relevant to BPH Human evidence / possible role Important cautions
Plant sterol β-Sitosterol Vegetable oils, nuts, seeds, legumes and standardized phytosterol extracts May modulate cholesterol-dependent membrane signalling, inflammation, androgen-associated growth and prostate smooth-muscle function. Moderate but older short-term evidence suggests improvement in urinary symptom scores and maximum urinary flow. It has not been shown to reliably reduce prostate size or prevent urinary retention and surgery. Possible gastrointestinal effects. Avoid in sitosterolemia. Long-term BPH efficacy and optimal extract composition remain uncertain.
Palm-fruit extract Saw palmetto
Serenoa repens		 Extract of ripe saw-palmetto berries Proposed inhibition of 5α-reductase, reduced DHT signalling, anti-inflammatory activity and modulation of adrenergic and muscarinic signalling. Evidence is inconsistent. Large trials of many commercial extracts found little or no benefit over placebo. Some evidence supports a small symptomatic effect from specifically standardized hexane-extracted preparations. Results from one extraction method cannot be generalized to all products. May cause abdominal discomfort, headache or dizziness. Use cautiously with anticoagulant or antiplatelet drugs.
Hexane-extracted Serenoa repens
(HESr)		 Standardized lipidosterolic saw-palmetto extract Anti-inflammatory effects and possible inhibition of androgen-dependent prostate growth and smooth-muscle contraction. May provide modest improvement in urinary symptoms and flow. Some European guidelines allow it as an option for men who specifically prefer a plant-derived therapy and accept limited benefit. The clinical effect is generally smaller and less predictable than standard pharmaceutical therapy. Product identity and extraction method are critical.
Tree-bark extract Pygeum / African plum
Prunus africana		 Standardized bark extract Contains phytosterols and triterpenes that may reduce inflammation, inhibit growth-factor signalling and alter bladder contractility. Older short-duration trials suggest modest improvement in nocturia, urinary flow and global urinary symptoms. Modern high-quality evidence is limited. Gastrointestinal discomfort and headache may occur. Bark harvesting has raised sustainability and product-authenticity concerns.
Pollen extract Rye-grass pollen extract
Secale cereale pollen / Cernilton		 Standardized grass-pollen fractions Proposed anti-inflammatory activity, smooth-muscle relaxation and inhibition of prostate-cell growth. Small trials suggest possible improvement in nocturia and overall urinary symptoms. Evidence for increased urinary flow or reduced prostate size is inconsistent. Avoid in people with relevant pollen allergy. Preparations are not interchangeable and supporting trials are generally small or old.
Seed-derived product Pumpkin seed
Cucurbita pepo		 Whole pumpkin seeds or seed extract Provides phytosterols, fatty acids, tocopherols and other compounds that may reduce inflammation and influence androgen-associated prostate growth. Several trials report modest improvements in symptom scores, nocturia and quality of life, but the evidence is insufficient to establish equivalence to α-blockers or 5α-reductase inhibitors. Generally well tolerated. Seed, oil and standardized soft extracts may produce different effects and should not be treated as equivalent products.
Pumpkin seed oil Cucurbita pepo seed oil Fatty acids and phytosterols may influence inflammatory and androgen-dependent pathways. Limited clinical studies suggest possible symptomatic improvement, including reduced nocturia. Evidence remains preliminary. May cause mild gastrointestinal symptoms. Combination studies cannot determine how much benefit is attributable to pumpkin seed oil alone.
Herbal root extract Stinging nettle root
Urtica dioica		 Root extract; not the leaf preparation Proposed inhibition of inflammatory pathways, aromatase, sex-hormone-binding interactions and prostate-cell proliferation. Some small trials and combination-product studies report improvement in urinary symptoms. Evidence for nettle-root monotherapy is limited. May have additive effects with antihypertensive, diuretic or glucose-lowering drugs. Root and leaf extracts have different compositions and uses.
Fruit polyphenol mixture Pomegranate extract Punica granatum fruit, juice or peel extracts Antioxidant and anti-inflammatory effects; may inhibit NF-κB, cytokine signalling and growth-associated pathways. BPH-specific clinical evidence is inadequate. It should be considered experimental rather than an established treatment. Concentrated products may interact with anticoagulants, antihypertensives or drugs metabolized by hepatic enzymes.
Carotenoid Lycopene Tomatoes, tomato paste, watermelon and supplements Antioxidant and anti-inflammatory activity; proposed modulation of IGF signalling, androgen signalling and prostate-cell proliferation. Small studies suggest possible slowing of prostate enlargement or improved symptoms, particularly in combination formulations. Evidence is insufficient for use as BPH monotherapy. Generally well tolerated. It must not be used to delay evaluation of an elevated PSA or other possible prostate-cancer findings.
Isoflavone Soy isoflavones
Genistein and daidzein		 Soybeans, soy foods and concentrated extracts Weak selective estrogen-receptor activity, antioxidant effects and possible inhibition of growth-factor and androgen-associated signalling. Epidemiological and mechanistic findings are of interest, but controlled evidence for meaningful treatment of established BPH is inadequate. Concentrated extracts may affect thyroid-drug absorption. Clinical effects may depend on dose, metabolism and intestinal conversion to equol.
Polyphenol Green-tea catechins
EGCG		 Camellia sinensis tea or concentrated extract Antioxidant and anti-inflammatory effects; may inhibit NF-κB, growth-factor signalling and prostate-cell proliferation. No reliable evidence establishes green-tea extract as a treatment for BPH. Most support is mechanistic, preclinical or derived from prostate-cancer prevention research rather than BPH trials. Concentrated extracts can cause liver injury, particularly when taken fasting. Tea and extracts can also affect iron absorption and interact with some drugs.
Polyphenol Curcumin Turmeric rhizome
Curcuma longa		 May suppress NF-κB, COX-2, inflammatory cytokines, oxidative stress and growth-associated signalling. BPH evidence is preliminary and usually involves multi-ingredient products. Curcumin alone is not an established BPH therapy. May increase bleeding tendency and cause gastrointestinal or gallbladder symptoms. Formulations with enhanced bioavailability can alter interaction risk.
Fatty acid Omega-3 fatty acids
EPA and DHA		 Fish oil, algal oil and oily fish Generate inflammation-resolving lipid mediators and may reduce inflammatory eicosanoid signalling. No convincing clinical evidence supports omega-3 supplementation as a direct treatment for BPH or bladder-outlet obstruction. High supplemental doses may increase bruising or bleeding and may interact with anticoagulants. Use primarily for established nutritional or cardiovascular indications, not specifically for BPH.
Vitamin Vitamin D Vitamin D3, vitamin D2 and sunlight-dependent synthesis Vitamin-D receptor signalling may regulate inflammation, cell differentiation and prostate-cell proliferation. Low vitamin-D status has been associated with BPH in some observational studies, but supplementation has not been established as an effective BPH treatment. Correct confirmed deficiency for general health. Excess dosing can cause hypercalcemia, kidney stones and renal injury. Check serum status when high-dose treatment is contemplated.
Vitamin E
α-Tocopherol and mixed tocopherols		 Vegetable oils, nuts, seeds and supplements Lipid-phase antioxidant that may reduce membrane lipid peroxidation and inflammatory signalling. There is no adequate clinical evidence that vitamin E treats BPH or improves urinary obstruction. High-dose supplementation may increase bleeding risk. Large preventive trials have raised concerns regarding high-dose α-tocopherol in men.
Vitamin C Citrus fruits, vegetables and ascorbic-acid supplements Water-soluble antioxidant and enzymatic cofactor; may modulate oxidative and inflammatory processes. No reliable clinical evidence supports vitamin C supplementation as a treatment for BPH. High doses may cause diarrhea and increase urinary oxalate or kidney-stone risk in susceptible individuals.
Vitamin B6 Pyridoxine or pyridoxal-5-phosphate Enzymatic cofactor involved in amino-acid, neurotransmitter and one-carbon metabolism. No established clinical role in BPH treatment. Supplement only for a documented deficiency or another recognized indication. Chronic high-dose pyridoxine can cause sensory neuropathy.
Mineral / nutritional element Zinc Meat, shellfish, dairy, legumes, seeds and zinc salts The normal prostate accumulates zinc, which affects citrate metabolism, antioxidant defence, apoptosis and androgen-associated biology. Zinc concentrations may be altered in BPH tissue, but zinc supplementation has not been shown to reliably improve prostate size, urinary flow or BPH symptoms. Correct confirmed zinc deficiency rather than treating BPH empirically. Long-term high doses can cause copper deficiency, anemia and neurologic effects. Doses above approximately 40 mg/day elemental zinc generally require clinical justification; very high long-term intake has been associated observationally with increased risk of aggressive prostate cancer.
Selenium Brazil nuts, seafood, meat and selenomethionine or sodium-selenite supplements Cofactor for glutathione peroxidases and other selenoproteins involved in redox and thyroid-hormone metabolism. Selenium is not an established treatment for BPH. Supplementation has not demonstrated reliable improvement in urinary symptoms or prostate volume. Excess causes selenosis, including hair and nail changes, gastrointestinal symptoms, neuropathy and garlic-like breath. Brazil-nut selenium content is highly variable.
Magnesium Green vegetables, nuts, whole grains and magnesium salts Supports neuromuscular function, ATP-dependent reactions and smooth-muscle physiology. No direct clinical evidence establishes magnesium as a treatment for BPH. Correcting deficiency may support general metabolic and muscular function but should not be expected to reduce prostate obstruction. Supplements can cause diarrhea. Magnesium can accumulate in severe renal impairment and can reduce absorption of some antibiotics and thyroid medication.
Boron Fruits, nuts, legumes and borate supplements May influence steroid-hormone, vitamin-D, inflammatory and mineral metabolism. Evidence is mechanistic or observational. There is no reliable clinical evidence that boron supplementation treats BPH. Therapeutic dosing and long-term safety for BPH are not established. Excess boron can cause gastrointestinal, dermatologic, neurologic and reproductive toxicity.
Metal-containing product Metallic silver / colloidal silver Suspensions of elemental silver particles or silver ions No plausible clinically validated mechanism for treating BPH. No evidence supports colloidal silver for BPH. It should not be included as an active BPH therapy. Can cause permanent argyria, kidney or neurologic toxicity and drug interactions. Silver is not an essential nutrient.
Metal-containing product Germanium products Organic or inorganic germanium supplements Claims generally involve immune modulation or antioxidant effects, but no validated BPH mechanism has been demonstrated. No credible evidence supports germanium supplementation for BPH. Germanium supplements have been associated with serious renal toxicity, neurologic toxicity and death. They should be avoided.
Combination nutraceutical Saw palmetto + β-sitosterol + pygeum + pumpkin seed or nettle root Commercial multi-ingredient prostate formulas Combines proposed antiandrogenic, anti-inflammatory, phytosterol and bladder-modulating mechanisms. Some combinations report symptom improvement, but attribution to a specific ingredient is usually impossible. Evidence for the exact formulation is required and cannot be inferred from studies of its individual components. Greater interaction and adverse-effect uncertainty. Ingredient quantities may be subtherapeutic, proprietary or inconsistent between batches.

Procedures

Intervention class Procedure / intervention Mechanism or technique Typical role / patient selection Major advantages Limitations, adverse effects and cautions
Conservative management Watchful waiting / active surveillance Symptoms, urinary flow, post-void residual volume, prostate findings and complications are monitored without immediate pharmaceutical or procedural treatment. Appropriate for mild or minimally bothersome lower urinary tract symptoms without urinary retention, recurrent infection, bladder stones, renal impairment or other high-risk complications. Avoids medication adverse effects and procedural complications. Symptoms or obstruction may progress. Periodic reassessment is required, especially if urinary retention, infection, hematuria or renal dysfunction develops.
Behavioral and lifestyle modification Reduces aggravating factors through evening fluid restriction, timed voiding, double voiding, management of constipation, physical activity and reduced intake of alcohol or caffeine. Used for mild symptoms or as an adjunct to medication and procedural treatment. Non-invasive, inexpensive and may reduce nocturia, urgency and frequency. Does not remove fixed prostatic obstruction or substantially reduce prostate size. Excessive fluid restriction can cause dehydration.
Medication review Identifies drugs that may worsen urinary symptoms, including some decongestants, antihistamines, anticholinergics, opioids and diuretics. Useful when symptoms began or worsened after a medication change. May improve symptoms without prostate-directed treatment. Prescription drugs should not be discontinued without appropriate medical review. The offending medication may be medically necessary.
Bladder drainage and retention management Temporary urethral catheterization A catheter is passed through the urethra into the bladder to immediately drain retained urine. Acute urinary retention, severe post-void residual volume, painful bladder distension, obstructive renal dysfunction or temporary perioperative drainage. Rapidly relieves bladder distension and protects the upper urinary tract. Infection, urethral trauma, bleeding, discomfort, bladder spasms and catheter blockage. It does not treat the underlying prostate obstruction.
Trial without catheter The catheter is removed after a period of drainage, frequently after initiation of an α1-blocker, to determine whether spontaneous voiding can resume. Common after a first episode of BPH-associated acute urinary retention. May avoid long-term catheterization or immediate surgery. Retention may recur. Failure generally requires recatheterization and further investigation or definitive treatment.
Clean intermittent catheterization The bladder is periodically emptied using a temporary catheter that is removed after each drainage. Chronic incomplete emptying, detrusor underactivity, or patients who are awaiting or unsuitable for definitive treatment. Usually produces fewer long-term catheter complications than a continuously indwelling urethral catheter. Requires dexterity, vision, training and adherence. Urinary infection, urethral trauma and false passages can occur.
Suprapubic catheterization A catheter is inserted through the lower abdominal wall directly into the bladder. Longer-term drainage when urethral catheterization is unsuitable, poorly tolerated or associated with urethral damage. Avoids continuous urethral pressure and may be more comfortable for prolonged drainage. Requires a procedure and ongoing catheter care. Infection, bladder stones, leakage, blockage and tract complications may occur.
Minimally invasive mechanical procedures Prostatic urethral lift
PUL / UroLift 		Permanent implants retract obstructing prostatic lobes away from the urethral lumen without cutting or thermally destroying tissue. Commonly considered for selected small-to-moderate prostates, particularly when preservation of erectile and ejaculatory function is a high priority. Suitability depends on prostate anatomy and the nature of any median lobe. Usually outpatient; rapid recovery; generally preserves antegrade ejaculation and erectile function; little tissue destruction. Less improvement in flow and symptoms than tissue-removing surgery. Retreatment is more frequent than after TURP or enucleation. Dysuria, hematuria, urgency and implant-related complications may occur.
Temporary implanted nitinol device
iTind 		A temporary expanding nitinol device is placed in the prostatic urethra for several days. Its struts remodel or incise the bladder neck and prostatic urethra through localized pressure. Selected patients with small-to-moderate glands who prioritize preservation of sexual function and wish to avoid permanent implants or tissue ablation. Temporary device; no permanent implant; generally low risk of erectile or ejaculatory dysfunction. Less long-term evidence than TURP or HoLEP. Temporary pelvic discomfort, urgency, dysuria, hematuria, urinary infection and retention may occur. Not suitable for every prostate configuration.
Prostatic stent A temporary or permanent stent holds the prostatic urethra open to permit urine flow. Occasionally used in patients who cannot tolerate definitive surgery or anesthesia and who wish to avoid a chronic catheter. Can provide urine flow without removal of prostate tissue. Migration, encrustation, infection, pain, urgency, obstruction and difficult removal can occur. Routine use is limited.
Minimally invasive tissue-ablation procedures Water-vapor thermal therapy
WVTT / Rezūm 		Controlled steam injections transfer thermal energy into prostate tissue, causing cellular necrosis. The treated tissue is gradually resorbed, enlarging the urethral channel. Typically used for selected small-to-moderate prostates. It can treat some obstructing median lobes and is frequently selected when preservation of ejaculation is important. Office or outpatient procedure; generally preserves erectile and ejaculatory function; no permanent implant; can treat median-lobe tissue. Improvement is delayed for weeks to months. Temporary catheterization is common. Dysuria, urgency, hematuria, infection and temporary retention may occur. Retreatment rates exceed those of definitive tissue-removing surgery.
Transurethral microwave thermotherapy
TUMT 		Microwave energy delivered through a urethral catheter heats and destroys portions of obstructing prostate tissue. Historically used as a minimally invasive alternative for selected patients wishing to avoid conventional surgery. Can be performed without major surgery and sometimes with limited anesthesia. Less effective and less durable than TURP. Retreatment and prolonged catheterization are relatively common. It is now used less frequently.
Transurethral needle ablation
TUNA 		Needles placed through the urethra deliver radiofrequency energy into the prostate, producing localized thermal necrosis. Older minimally invasive option for selected patients with moderate obstruction. Limited blood loss and lower perioperative burden than conventional surgery. Lower efficacy and durability than modern resection or enucleation. Largely replaced by newer technologies.
Transurethral laser coagulation / vaporization variants Laser energy heats, coagulates or vaporizes obstructing tissue to enlarge the prostatic urethral channel. Technique and suitability depend on laser platform, prostate volume, anticoagulation status and surgeon expertise. Reduced bleeding compared with traditional monopolar resection in many settings. Postoperative dysuria, urinary retention, bladder-neck contracture, urethral stricture and ejaculatory dysfunction may occur.
Transurethral incision Transurethral incision of the prostate
TUIP 		One or two incisions are made through the bladder neck and prostate to reduce constriction without removing substantial tissue. Best suited to selected men with relatively small prostates and bladder-neck obstruction, generally without a large median lobe. Short procedure, limited bleeding, shorter recovery and a lower rate of retrograde ejaculation than standard TURP. Not appropriate for large prostates. Retreatment is more frequent than after TURP because little or no tissue is removed.
Transurethral tissue resection Monopolar transurethral resection of the prostate
Monopolar TURP 		An electrified wire loop passed through a resectoscope cuts obstructing prostate tissue into chips that are removed through the urethra. Long-established standard treatment for moderate-to-severe obstruction, particularly in small-to-moderate prostate glands. Strong and generally durable improvement in urinary flow, symptom scores and bladder emptying. Tissue is available for histopathology. Bleeding, transfusion, urinary infection, clot retention, urethral stricture, bladder-neck contracture, temporary urgency and urinary retention may occur. Retrograde ejaculation is common. Rare dilutional hyponatremia or TUR syndrome can occur with monopolar irrigation.
Bipolar transurethral resection of the prostate
Bipolar TURP 		Bipolar electrical energy resects prostate tissue while saline is used as the irrigation solution. Similar indications to monopolar TURP and now frequently preferred where equipment and expertise are available. Comparable symptom relief to monopolar TURP with minimal risk of classic dilutional TUR syndrome and potentially improved hemostasis. Bleeding, infection, stricture, bladder-neck contracture and retrograde ejaculation remain possible. General or spinal anesthesia is commonly used.
Bipolar transurethral enucleation
B-TUEP / bipolar enucleation 		The obstructing adenoma is dissected from the surgical capsule using bipolar energy and subsequently removed or morcellated. Can be used across a broad range of prostate sizes, including relatively large glands, when appropriate expertise is available. More complete tissue removal than conventional resection; durable results; saline irrigation; tissue available for pathology. Technically demanding. Temporary stress incontinence, bleeding, stricture, bladder injury during morcellation and retrograde ejaculation may occur.
Laser surgery Holmium laser enucleation of the prostate
HoLEP 		A holmium laser separates the enlarged adenoma from the prostate capsule. The tissue is pushed into the bladder, mechanically morcellated and removed. Size-independent definitive treatment suitable for small, medium, large and very large prostates when performed by an experienced surgeon. Major and durable symptom improvement; low transfusion risk; short catheter duration; tissue available for pathology; useful for patients at increased bleeding risk. Requires specialized training and equipment. Temporary stress urinary incontinence can occur, particularly early in recovery. Retrograde ejaculation is very common. Urethral stricture or bladder-neck contracture is possible.
Thulium laser enucleation of the prostate
ThuLEP / ThuFLEP 		Thulium laser energy is used to dissect the obstructing adenoma from the surgical capsule, followed by tissue morcellation. Alternative laser-enucleation technique for a broad range of prostate sizes. Effective hemostasis, substantial tissue removal and durable relief comparable to other well-performed enucleation techniques. Availability and outcomes depend strongly on surgeon experience. Temporary incontinence, stricture, bleeding and retrograde ejaculation may occur.
Photoselective vaporization of the prostate
PVP / GreenLight laser 		Laser energy is preferentially absorbed by hemoglobin and vaporizes obstructing prostate tissue while producing hemostasis. Often considered for small-to-moderate glands and for patients with elevated bleeding risk or those taking antithrombotic therapy, depending on individual assessment. Low intraoperative bleeding, saline irrigation, relatively short catheterization and hospitalization. No substantial tissue specimen is normally obtained for pathology. Dysuria may persist during healing. Retreatment may be more common with large glands or incomplete vaporization. Retrograde ejaculation is common.
Holmium laser resection or vaporization
HoLAP / HoLRP 		Holmium laser energy vaporizes or resects obstructing prostate tissue without performing complete anatomical enucleation. Selected smaller prostates or settings in which complete HoLEP is not used. Good hemostasis and use of saline irrigation. Less complete tissue removal than enucleation and potentially less durable for large glands. Availability varies.
Robotically guided waterjet resection Aquablation therapy
Robotic waterjet treatment 		Real-time transrectal ultrasound and computer-controlled planning guide a high-pressure, heat-free waterjet that removes obstructing tissue. Used for moderate-to-severe LUTS across a range of prostate sizes, including selected larger glands and complex anatomy. May be attractive when preservation of ejaculation is an important objective. Rapid and substantial symptom improvement; treatment planning is relatively independent of manual resection speed; lower ejaculatory dysfunction than conventional TURP in many studies. Usually requires anesthesia and operating-room resources. Postoperative bleeding and the need for cautery, catheterization or hospitalization remain possible. Long-term evidence is less extensive than for TURP or HoLEP.
Endovascular intervention Prostatic artery embolization
PAE 		An interventional radiologist passes a catheter through an artery and injects microscopic embolic particles into the prostatic arteries, reducing blood supply and causing gradual prostate shrinkage. May be considered for selected patients who prefer a non-transurethral intervention, have a large prostate, have elevated surgical or anesthesia risk, or prioritize preservation of ejaculation. No transurethral tissue resection; usually performed with local anesthesia and sedation; low rates of erectile and ejaculatory dysfunction. Symptom and flow improvement are generally less predictable and may be less pronounced than after TURP or enucleation. Retreatment may be more common. Requires appropriate pelvic arterial anatomy and experienced interventional radiology. Non-target embolization, pelvic pain, dysuria, hematuria, infection and temporary retention may occur.
Simple prostatectomy Open simple prostatectomy The inner obstructing prostatic adenoma is surgically removed through an abdominal incision while the outer prostate capsule remains in place. Traditionally used for very large prostates, particularly when large bladder stones, diverticula or other open bladder surgery is also required. Removes a large volume of obstructing tissue and provides major, durable improvement. Tissue is available for pathology. More invasive than transurethral surgery. Greater blood loss, transfusion risk, postoperative pain, catheter duration, hospitalization and recovery time. Retrograde ejaculation is expected in most patients.
Laparoscopic simple prostatectomy The adenoma is removed through several small abdominal incisions using laparoscopic instruments. Large or very large prostates when endoscopic enucleation is unavailable or another abdominal procedure is required. Less blood loss and shorter recovery than open surgery in experienced hands. Requires general anesthesia and advanced laparoscopic expertise. Urine leakage, bleeding, infection, bladder-neck contracture, incontinence and retrograde ejaculation may occur.
Robotic-assisted simple prostatectomy
RASP 		Robotic instruments are used through small abdominal ports to remove the obstructing adenoma while preserving the prostate capsule. Large or very large prostates, especially when a robotic approach is available or concurrent bladder pathology requires treatment. Excellent visualization, effective removal of large adenomas, lower blood loss and shorter hospitalization than open surgery in many centers. More invasive and costly than transurethral enucleation; requires general anesthesia and specialized equipment. Retrograde ejaculation is common, and bleeding, infection, leakage, stricture or incontinence may occur.
Emerging, restricted or investigational interventions Drug-coated balloon dilation A transurethral balloon expands the prostatic urethra and may deliver an antiproliferative drug to reduce recurrent narrowing. Emerging option for selected BPH-associated obstruction. Regulatory status, evidence and availability vary by jurisdiction. Minimally invasive and potentially preserves sexual function. Long-term comparative durability and optimal patient selection remain uncertain. It should not automatically be considered equivalent to established resection or enucleation procedures.
Temporary transperineal implantable nitinol device Experimental or evolving implant systems mechanically reshape the prostatic urethra or compress obstructing tissue. Selected clinical programs or trials. Potential outpatient treatment with limited thermal injury. Device-specific evidence, regulatory approval, long-term durability and retreatment rates must be established separately.
High-intensity focused ultrasound or other focal-energy systems Focused acoustic or thermal energy is used experimentally to ablate obstructing benign prostate tissue. Investigational for routine BPH treatment; should be distinguished from focal therapy for prostate cancer. Potentially non-incisional or minimally invasive. Insufficient evidence for routine BPH treatment. Availability may be limited to research protocols.


Scientific Papers found: Click to Expand⟱
4621- Bor,    Boron
- Review, BPH, NA
*other↝, Risk↑, *Dose↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Functional Outcomes(tgid=23) ⓘ

Risk↑, 1,  
Total Targets: 1

Pathway results for Effect on Normal Cells:


Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↑, 1,  
Total Targets: 2

Scientific Paper Hit Count for: other, other
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:86  Cells:%  prod#:%  Target#:767  State#:%  Dir#:4
  wNotes=0  sortOrder:rid,rpid

 

Home Page